Which has higher earnings and valuation, TECX or ADAG?

Adagene has higher revenue and earnings than Tectonic Therapeutic. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tectonic Therapeutic N/A N/A -$74.15M -$4.57 N/A Adagene $9.29M 19.89 -$17.61M N/A N/A

Is TECX or ADAG more profitable?

Adagene's return on equity of 0.00% beat Tectonic Therapeutic's return on equity. Company Net Margins Return on Equity Return on Assets Tectonic Therapeutic N/A -35.26% -33.59% Adagene N/A N/A N/A

Does the media refer more to TECX or ADAG?

In the previous week, Tectonic Therapeutic had 1 more articles in the media than Adagene. MarketBeat recorded 3 mentions for Tectonic Therapeutic and 2 mentions for Adagene. Tectonic Therapeutic's average media sentiment score of 1.11 beat Adagene's score of 0.50 indicating that Tectonic Therapeutic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tectonic Therapeutic 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adagene 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ADAG or AVTE?

Adagene presently has a consensus target price of $10.00, indicating a potential upside of 156.41%. Given Adagene's stronger consensus rating and higher probable upside, equities research analysts plainly believe Adagene is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adagene 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, ADAG or AVTE?

Adagene has higher revenue and earnings than Aerovate Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adagene $9.29M 19.89 -$17.61M N/A N/A Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A

Is ADAG or AVTE more profitable?

Adagene's return on equity of 0.00% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Adagene N/A N/A N/A Aerovate Therapeutics N/A -90.19% -77.47%

Which has higher valuation & earnings, ADAG or VALN?

Adagene has higher earnings, but lower revenue than Valneva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adagene $9.29M 19.89 -$17.61M N/A N/A Valneva $142.94M 4.48 -$130.33M -$2.11 N/A

Is ADAG or VALN more profitable?

Adagene has a net margin of 0.00% compared to Valneva's net margin of -110.33%. Adagene's return on equity of 0.00% beat Valneva's return on equity. Company Net Margins Return on Equity Return on Assets Adagene N/A N/A N/A Valneva -110.33% -153.20% -39.50%

Does the media prefer ADAG or VALN?

In the previous week, Valneva had 8 more articles in the media than Adagene. MarketBeat recorded 10 mentions for Valneva and 2 mentions for Adagene. Adagene's average media sentiment score of 0.50 beat Valneva's score of 0.01 indicating that Adagene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adagene 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Valneva 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, ADAG or VSTM?

Adagene has higher earnings, but lower revenue than Verastem. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adagene $9.29M 19.89 -$17.61M N/A N/A Verastem $30.91M 20.10 -$209.47M -$2.66 N/A

Is ADAG or VSTM more profitable?

Adagene has a net margin of 0.00% compared to Verastem's net margin of -231.59%. Adagene's return on equity of 0.00% beat Verastem's return on equity. Company Net Margins Return on Equity Return on Assets Adagene N/A N/A N/A Verastem -231.59% -467.49% -94.54%

Does the media favor ADAG or VSTM?

In the previous week, Adagene had 1 more articles in the media than Verastem. MarketBeat recorded 2 mentions for Adagene and 1 mentions for Verastem. Verastem's average media sentiment score of 0.71 beat Adagene's score of 0.50 indicating that Verastem is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adagene 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verastem 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, SLN or ADAG?

Adagene has higher revenue and earnings than Silence Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Silence Therapeutics $615K 1,021.00 -$88.61M -$1.28 N/A Adagene $9.29M 19.89 -$17.61M N/A N/A

Does the media refer more to SLN or ADAG?

In the previous week, Silence Therapeutics had 13 more articles in the media than Adagene. MarketBeat recorded 15 mentions for Silence Therapeutics and 2 mentions for Adagene. Silence Therapeutics' average media sentiment score of 0.84 beat Adagene's score of 0.50 indicating that Silence Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Silence Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adagene 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Adagene (ADAG) Competitors

$3.90 -0.12 (-2.99%)

Closing price 04:00 PM Eastern

Extended Trading

$3.90 0.00 (0.00%)

As of 04:10 PM Eastern

Compare

ADAG vs. TECX, AVTE, VALN, VSTM, and SLN

Should you buy Adagene stock or one of its competitors? Adagene's main competitors and comparable companies include Tectonic Therapeutic (TECX), Aerovate Therapeutics (AVTE), Valneva (VALN), Verastem (VSTM), and Silence Therapeutics (SLN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Adagene compare to Tectonic Therapeutic?

Tectonic Therapeutic (NASDAQ:TECX) and Adagene (NASDAQ:ADAG) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation.

62.6% of Tectonic Therapeutic shares are owned by institutional investors. Comparatively, 9.5% of Adagene shares are owned by institutional investors. 39.8% of Tectonic Therapeutic shares are owned by insiders. Comparatively, 21.2% of Adagene shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Tectonic Therapeutic had 1 more articles in the media than Adagene. MarketBeat recorded 3 mentions for Tectonic Therapeutic and 2 mentions for Adagene. Tectonic Therapeutic's average media sentiment score of 1.11 beat Adagene's score of 0.50 indicating that Tectonic Therapeutic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tectonic Therapeutic	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adagene	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tectonic Therapeutic has a beta of 3.28, indicating that its share price is 228% more volatile than the broader market. Comparatively, Adagene has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market.

Tectonic Therapeutic currently has a consensus target price of $77.80, indicating a potential upside of 113.33%. Adagene has a consensus target price of $10.00, indicating a potential upside of 156.41%. Given Adagene's higher probable upside, analysts clearly believe Adagene is more favorable than Tectonic Therapeutic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Adagene	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Adagene has higher revenue and earnings than Tectonic Therapeutic.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.57	N/A
Adagene	$9.29M	19.89	-$17.61M	N/A	N/A

Adagene's return on equity of 0.00% beat Tectonic Therapeutic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-35.26%	-33.59%
Adagene	N/A	N/A	N/A

Summary

Tectonic Therapeutic beats Adagene on 8 of the 13 factors compared between the two stocks.

How does Adagene compare to Aerovate Therapeutics?

Adagene (NASDAQ:ADAG) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.

Adagene has higher revenue and earnings than Aerovate Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagene	$9.29M	19.89	-$17.61M	N/A	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

Adagene presently has a consensus target price of $10.00, indicating a potential upside of 156.41%. Given Adagene's stronger consensus rating and higher probable upside, equities research analysts plainly believe Adagene is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagene	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Adagene has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

9.5% of Adagene shares are held by institutional investors. 21.2% of Adagene shares are held by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Adagene's return on equity of 0.00% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adagene	N/A	N/A	N/A
Aerovate Therapeutics	N/A	-90.19%	-77.47%

In the previous week, Adagene had 2 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 2 mentions for Adagene and 0 mentions for Aerovate Therapeutics. Adagene's average media sentiment score of 0.50 beat Aerovate Therapeutics' score of 0.00 indicating that Adagene is being referred to more favorably in the media.

Company	Overall Sentiment
Adagene	Positive
Aerovate Therapeutics	Neutral

Summary

Adagene beats Aerovate Therapeutics on 11 of the 13 factors compared between the two stocks.

How does Adagene compare to Valneva?

Adagene (NASDAQ:ADAG) and Valneva (NASDAQ:VALN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Adagene has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market. Comparatively, Valneva has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market.

Adagene has higher earnings, but lower revenue than Valneva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagene	$9.29M	19.89	-$17.61M	N/A	N/A
Valneva	$142.94M	4.48	-$130.33M	-$2.11	N/A

9.5% of Adagene shares are owned by institutional investors. Comparatively, 11.4% of Valneva shares are owned by institutional investors. 21.2% of Adagene shares are owned by company insiders. Comparatively, 14.9% of Valneva shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Valneva had 8 more articles in the media than Adagene. MarketBeat recorded 10 mentions for Valneva and 2 mentions for Adagene. Adagene's average media sentiment score of 0.50 beat Valneva's score of 0.01 indicating that Adagene is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adagene	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Valneva	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Adagene has a net margin of 0.00% compared to Valneva's net margin of -110.33%. Adagene's return on equity of 0.00% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adagene	N/A	N/A	N/A
Valneva	-110.33%	-153.20%	-39.50%

Adagene currently has a consensus target price of $10.00, indicating a potential upside of 156.41%. Valneva has a consensus target price of $11.98, indicating a potential upside of 77.48%. Given Adagene's stronger consensus rating and higher probable upside, equities analysts clearly believe Adagene is more favorable than Valneva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagene	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Valneva	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Adagene beats Valneva on 10 of the 15 factors compared between the two stocks.

How does Adagene compare to Verastem?

Adagene (NASDAQ:ADAG) and Verastem (NASDAQ:VSTM) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

Adagene currently has a consensus price target of $10.00, suggesting a potential upside of 156.41%. Verastem has a consensus price target of $13.83, suggesting a potential upside of 101.65%. Given Adagene's higher probable upside, research analysts plainly believe Adagene is more favorable than Verastem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagene	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Verastem	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

Adagene has higher earnings, but lower revenue than Verastem.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagene	$9.29M	19.89	-$17.61M	N/A	N/A
Verastem	$30.91M	20.10	-$209.47M	-$2.66	N/A

Adagene has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market. Comparatively, Verastem has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market.

In the previous week, Adagene had 1 more articles in the media than Verastem. MarketBeat recorded 2 mentions for Adagene and 1 mentions for Verastem. Verastem's average media sentiment score of 0.71 beat Adagene's score of 0.50 indicating that Verastem is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adagene	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Verastem	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adagene has a net margin of 0.00% compared to Verastem's net margin of -231.59%. Adagene's return on equity of 0.00% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adagene	N/A	N/A	N/A
Verastem	-231.59%	-467.49%	-94.54%

9.5% of Adagene shares are held by institutional investors. Comparatively, 88.4% of Verastem shares are held by institutional investors. 21.2% of Adagene shares are held by insiders. Comparatively, 1.9% of Verastem shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Adagene beats Verastem on 8 of the 15 factors compared between the two stocks.

How does Adagene compare to Silence Therapeutics?

Silence Therapeutics (NASDAQ:SLN) and Adagene (NASDAQ:ADAG) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

Adagene has higher revenue and earnings than Silence Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$615K	1,021.00	-$88.61M	-$1.28	N/A
Adagene	$9.29M	19.89	-$17.61M	N/A	N/A

In the previous week, Silence Therapeutics had 13 more articles in the media than Adagene. MarketBeat recorded 15 mentions for Silence Therapeutics and 2 mentions for Adagene. Silence Therapeutics' average media sentiment score of 0.84 beat Adagene's score of 0.50 indicating that Silence Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Silence Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adagene	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Silence Therapeutics has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market. Comparatively, Adagene has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market.

Adagene has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. Adagene's return on equity of 0.00% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-8,943.86%	-106.94%	-47.99%
Adagene	N/A	N/A	N/A

98.7% of Silence Therapeutics shares are held by institutional investors. Comparatively, 9.5% of Adagene shares are held by institutional investors. 3.0% of Silence Therapeutics shares are held by insiders. Comparatively, 21.2% of Adagene shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Silence Therapeutics presently has a consensus target price of $53.50, indicating a potential upside of 302.56%. Adagene has a consensus target price of $10.00, indicating a potential upside of 156.41%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Silence Therapeutics is more favorable than Adagene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Adagene	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

Silence Therapeutics beats Adagene on 8 of the 14 factors compared between the two stocks.

Get Adagene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADAG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADAG vs. The Competition

Export

Metric	Adagene	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$184.81M	$3.99B	$7.29B	$12.70B
Dividend Yield	N/A	3.64%	2.54%	10.79%
P/E Ratio	N/A	11.75	271.38	24.10
Price / Sales	19.89	1,394.70	638.44	90.36
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	5.20	17.26	11.18	6.40
Net Income	-$17.61M	-$22.72M	$3.46B	$348.28M
7 Day Performance	1.83%	2.89%	1.99%	0.91%
1 Month Performance	21.88%	9.74%	7.32%	5.10%
1 Year Performance	63.18%	54.81%	24.76%	16.16%

Adagene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADAG Adagene	2.3025 of 5 stars	$3.90 -3.0%	$10.00 +156.4%	+68.2%	$184.81M	$9.29M	N/A	260
TECX Tectonic Therapeutic	3.1932 of 5 stars	$36.61 +8.2%	$77.80 +112.5%	+43.7%	$682.47M	N/A	N/A	120	High Trading Volume
AVTE Aerovate Therapeutics	N/A	$23.45 -5.1%	N/A	+159.3%	$679.70M	N/A	N/A	20	High Trading Volume
VALN Valneva	2.4034 of 5 stars	$6.87 -2.7%	$11.98 +74.4%	-40.2%	$676.53M	$197.56M	N/A	700	Gap Down
VSTM Verastem	3.3079 of 5 stars	$7.43 +3.5%	$13.83 +86.2%	-24.1%	$650.24M	$87.53M	N/A	50	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADAG) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adagene (ADAG) Competitors

ADAG vs. TECX, AVTE, VALN, VSTM, and SLN

How does Adagene compare to Tectonic Therapeutic?

Summary

How does Adagene compare to Aerovate Therapeutics?

Summary

How does Adagene compare to Valneva?

Summary

How does Adagene compare to Verastem?

Summary

How does Adagene compare to Silence Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAG vs. The Competition

Adagene Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adagene (ADAG) Competitors

ADAG vs. TECX, AVTE, VALN, VSTM, and SLN

How does Adagene compare to Tectonic Therapeutic?

Do insiders & institutionals believe in TECX or ADAG?

Does the media refer more to TECX or ADAG?

Which has more risk & volatility, TECX or ADAG?

Do analysts rate TECX or ADAG?

Which has higher earnings and valuation, TECX or ADAG?

Is TECX or ADAG more profitable?

Summary

How does Adagene compare to Aerovate Therapeutics?

Which has better valuation and earnings, ADAG or AVTE?

Do analysts prefer ADAG or AVTE?

Which has more risk & volatility, ADAG or AVTE?

Do insiders and institutionals believe in ADAG or AVTE?

Is ADAG or AVTE more profitable?

Does the media prefer ADAG or AVTE?

Summary

How does Adagene compare to Valneva?

Which has more volatility & risk, ADAG or VALN?

Which has higher valuation & earnings, ADAG or VALN?

Do insiders & institutionals believe in ADAG or VALN?

Does the media prefer ADAG or VALN?

Is ADAG or VALN more profitable?

Do analysts rate ADAG or VALN?

Summary

How does Adagene compare to Verastem?

Do analysts rate ADAG or VSTM?

Which has better earnings and valuation, ADAG or VSTM?

Which has more risk & volatility, ADAG or VSTM?

Does the media favor ADAG or VSTM?

Is ADAG or VSTM more profitable?

Do insiders & institutionals have more ownership in ADAG or VSTM?

Summary

How does Adagene compare to Silence Therapeutics?

Which has stronger earnings & valuation, SLN or ADAG?

Does the media refer more to SLN or ADAG?

Which has more risk & volatility, SLN or ADAG?

Is SLN or ADAG more profitable?

Do insiders and institutionals believe in SLN or ADAG?

Do analysts prefer SLN or ADAG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAG vs. The Competition

Adagene Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools